Wire · operational-macro
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
The FDA granted Breakthrough Therapy designation to 64Cu-SAR-bisPSMA, an imaging agent for detecting recurrent prostate cancer, based on clinical trials showing superior lesion detection and improved diagnostic accuracy compared to the current standard, 68Ga-PSMA-11. This designation enables expedited development and regulatory review, with phase 3 trial results expected in 2027.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You have a faster route to market for a superior prostate cancer imaging agent thanks to the FDA’s Breakthrough Therapy tag. You must prepare for sharper competition as new diagnosis clarity shifts clinical management decisions.
◆ Coverage
1 source · 12 Nov 2026
◆ Related on Wire
◆ Topics